Akero Therapeutics (AKRO) PT Raised to $61 at Cantor Fitzgerald, 'we would be buyers'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Akero Therapeutics (AKRO) PT Raised to $50 at Evercore ISI
March 4, 2024 12:13 PM ESTEvercore ISI analyst Josh Schimmer raised the price target on Akero Therapeutics (NASDAQ: AKRO) to $50.00 (from $36.00) while maintaining a Outperform rating.... More
Akero Therapeutics (AKRO) PT Raised to $43 at H.C. Wainwright
March 4, 2024 6:44 AM ESTH.C. Wainwright analyst Ed Arce raised the price target on Akero Therapeutics (NASDAQ: AKRO) to $43.00 (from $40.00) while maintaining a Buy rating.... More
Akero Therapeutics (AKRO) Posts Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
March 4, 2024 6:02 AM ESTAkero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product... More
